Even if it's not being officially reported yet, its drug Casgevy is accruing revenue that will show

CRISPR Therapeutics will likely be a much larger company in 10 years. Much of that time will be spen

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or H

CRISPR Therapeutics AG (CRSP) reached $51.8 at the closing of the latest trading day, reflecting a -

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Theref

CRISPR Therapeutics NASDAQ: CRSP CEO Sam Kulkarni outlined the company's commercial and clinical pri

CRISPR Therapeutics AG (CRSP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Tr

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a

Amgen provides a stable foundation with multi-billion dollar revenues and consistent cash flows. CRI

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with m

The FDA-approved drug it helped developed saw a nearly 80% sequential rise in sales. It also booked

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicin

Successful pipeline development could substantially increase CRISPR's valuation. The upstart biotech

ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) t

Creative Medical Technology (NASDAQ: CELZ - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP -

Cathie Wood explains why Tesla, Coinbase, and CRISPR lead her "Rapid Real Growth" thesis as

CRISPR Therapeutics transitioned from speculative biotech to commercial stage with FDA approval of C

CRISPR Therapeutics' only approved product may experience increased demand. The biotech could also s

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co I

Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the fu

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

CRISPR Therapeutics (NASDAQ:CRSP) today presented durability data from its Phase 1a clinical trial e

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation,

Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on posi

Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and ra

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the anal

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) w

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Cathie Wood’s ARK Innovation ETF is shedding assets this year as it continues to underperform the te

Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Per

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and ra

Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overwei

CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshad

- CRISPR Therapeutics AG (NASDAQ:CRSP) (the "Company") today announced its intention to offe

US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving l

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes

Cathie Wood's Ark Invest unveiled its "big ideas" for 2025 in a cryptic list, challengin

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti